Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Rentschler Announces 3rd Industrial Cell Culture Technology Conference

Published: Saturday, March 15, 2014
Last Updated: Friday, March 14, 2014
Bookmark and Share
“Laupheimer Zelltage” to be held on June 2-3, 2014 in Laupheim, Germany.

Virus-based biologics play an increasing role in the development of innovative gene, immuno and virotherapeutics. Novel virus-based carrier technologies such as virus-like particles are breaking into new vaccine sectors.

The first approval of a gene therapeutic (Glybera®) in Europe as well as various reports of success from gene therapy trials are bolstering confidence in the potential of gene therapy. Also the development of oncolytic viruses for cancer immunotherapy is attracting more and more attention.

Common to all of these virus-based biologics is their high degree of complexity, creating the necessity for high levels of understanding of virus and cell biology as well as a multiplicity of innovative technologies. The manufacturing of virus-based biologics is setting new standards for process development and analytical and regulatory requirements.

Against this background Rentschler invites under the heading Processes for Virus-based Biologics to the third Industrial Cell Culture Technology Conference. The conference will take place on June 2-3, 2014 at Laupheim's historical castle, Schloss Großlaupheim.

With the Industrial Cell Culture Technology Conference “Laupheimer Zelltage” Rentschler has established a unique platform for the international exchange of knowledge, ideas and expertise.

Held every two years, it attracts global leaders and forward thinkers in the field of biotechnology. As these experts discuss the application of cutting-edge developments, important breakthroughs emerge in the manufacturing of biologics.

Processes for Virus-based Biologics include all aspects related to platform technologies for the manufacturing and control of viral biopharmaceuticals including viral vectors, oncolytic viruses and virus-based vaccines.

The conference will bring together international academic and industrial experts in cell culture and process technology for the production of virus-based biologics and is the first conference of its type eagerly awaited by the scientific and industrial community.

The keynote lecture will be held by Florian Wurm (Swiss Federal Institute of Technology). The full program and organization details can be found here: http://rentschler.de/en/information/laupheimer-zelltage/.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Rentschler Invests EUR 24 Million in Stainless Steel Bioreactor Manufacturing
The Twin system should be operational in early 2017.
Saturday, June 21, 2014
Rentschler Expands Single-Use Manufacturing Capacities
Company announces addition of a 2,000 L single-use bioreactor to its facility.
Saturday, June 07, 2014
New Campaign for Rentschler's 'Facility of the Year'
Company has launched a new website to coincide with BIO 2012.
Tuesday, July 17, 2012
Rentschler to Manufacture Faron Product Traumakine®
Rentschler will become the sole global manufacturer of IFN-beta 1a for Faron and also manufacture Faron’s proprietary bulk drug product.
Tuesday, January 18, 2011
Scientific News
Shedding Light on HIV Vaccine Design
Broadly speaking - Mathematical modelling of host-pathogen coevolution sheds light on HIV vaccine design.
Progress In Vaccination Against Vespid Venom
Researchers at the Helmholtz Zentrum München and the Technical University Munich have presented a method which facilitates a personalised procedure for wasp allergy sufferers.
FINCH Filgotinib Phase 3 Program Initiated
Galapagos NV reports the initiation of the FINCH global Phase 3 program in rheumatoid arthritis patient populations.
New Method of Cancer Immunotherapy
Stanford chemists have dicovered a new form of cancer immunotherapy using sugar presence manipulation.
Vortex Ring Freezing Applications
Accidental lab discovery could aid cell delivery and cell-free protein production.
Examining Immune Memory
Researchers investigate the 'storage/research for the future' functions of antibodies and understanding of B cells.
Expanding the Stable of Workhorse Yeasts
New genome sequences target the next generation of yeasts with improved biotechnology uses.
How Cloud Connectivity Can Combat the Reproducibility Crisis
This infographic explains the reproducibility crisis, and how cloud connectivity can help overcome this problem.
Blocking the Migration of Cancer Cells to Destroy Them
Scientists in Geneva developed an antibody able to fight off lymphomas.
Mutations Linked to Immunotherapy Resistance
Researchers uncover mutations in tumors of three patients with advanced melanoma that allowed the tumors to become resistant to the immune checkpoint inhibitor pembrolizumab (Keytruda®).
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!